Featured Articles

  1. Your Trial Shows Up In AI. Now What? 9/3/2026

    AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.

  2. Four Implications Of The Phase 3 Cancer Vaccine Results 9/1/2026

    Merck and Moderna's Phase 3 results in melanoma offer the strongest validation yet for personalized cancer vaccines, writes Devan Shah.

  3. When Should R&D Turn Back? 8/28/2026

    Good R&D leadership is knowing when to keep investing in a development program, when to change course, and when to return to base, writes David Adler, M.D./Ph.D., MBA.

  4. Connect The Dots: Precision Testing Leads To Patient Access In Oncology 8/24/2026

    Precision oncology only works when biomarker testing helps identify the right patients before launch, explains Boehringer Ingelheim’s Vicky Brown. 

  5. Nasdaq's New MVLS Rule: Rethinking Exchange Choice For Micro-Caps 8/21/2026

    Nasdaq’s new $5 million MVLS rule raises delisting risk for micro-cap life sciences companies, making exchange choice an ongoing board governance issue.

  6. What Biotech Leaders Can Learn From The Cockpit 8/18/2026

    Patrick Mooney, CEO of SpyGlass Pharma, shares how insights from the cockpit have shaped his approach to leading an innovative biotech.

  7. M&A In The Life Sciences Sector: Challenges And Opportunities 8/14/2026

    Life Sciences M&A policies in the EU, Israel, and Singapore are shifting, creating new opportunities for drug developers, according to legal experts at Meritas.

  8. Biotech Playbook Breakdown: Who Will Risk Developing Tomorrow's Cures? 8/11/2026

    Biotech’s old risk-sharing model is breaking down, forcing academia, investors, pharma, and healthcare systems to collaborate earlier to bring cures to patients.

  9. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

    Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

  10. Big Pharma Can't Merge Its Way Out Of An Innovation Problem 8/6/2026

    Mega-mergers may cut costs, but they won’t fix pharma’s innovation gap. Breakthroughs come through biotech partnerships, writes Sofinnova’s Jim Healy, M.D., Ph.D.